LAVAL, Quebec, June 11, 2015 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)
announced today that Robert L.
Rosiello was appointed as Executive Vice President and will
take over the role of Chief Financial Officer from Howard Schiller on July
1, 2015. Mr. Schiller will remain on Valeant's Board
and is expected to serve as a consultant to Valeant.
"The Board of Directors and I are delighted that Rob has agreed
to join Valeant," said J. Michael
Pearson, Chairman and Chief Executive Officer. "Rob is
someone I have worked closely with for 20 years. I know his
tremendous expertise in healthcare and in particular M&A, his
unquestioned intellect, and work ethic and integrity will prove to
be of great value to the Valeant organization and its shareholders.
I want to thank Howard for his strong leadership to both myself and
the entire organization these past few years and I will continue to
rely on his valuable counsel as a member of our Board of
Directors."
Mr. Rosiello worked 30 years at McKinsey & Company helping
healthcare, technology and consumer companies deliver growth
through M&A and business unit financial performance
improvement. As Senior Partner in charge of the global merger
practice for the past decade, Mr. Rosiello led M&A integrations
for pharmaceutical, specialty pharmaceutical and medical device
companies in the U.S., Europe and
Asia.
Mr. Rosiello serves on the Board of Catholic Charities of
New York, the Pew Research Center
and the Central Selection Committee of the Morehead Cain
Foundation. He received his BA in economics from the
University of North Carolina, where he
was a Morehead Scholar. He also earned an MS from the
London School of Economics and an MBA
from Harvard.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, eye health, neurology and
branded generics. More information about Valeant can be found at
www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements,
including, but not limited to, statements regarding the appointment
of Valeant's chief financial officer. Forward-looking
statements may generally be identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could,"
"would," "may," "will," "believes," "estimates," "potential,"
"target," or "continue" and variations or similar expressions.
These statements are based upon the current expectations and
beliefs of management of Valeant and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include the risks and uncertainties
discussed in Valeant's most recent annual or quarterly report and
detailed from time to time in Valeant's other filings with the
Securities and Exchange Commission (the "SEC") and the Canadian
Securities Administrators, which factors are incorporated herein by
reference. Readers are cautioned not to place undue reliance on any
of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. Valeant
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this press release or to reflect actual outcomes.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-to-appoint-robert-l-rosiello-as-chief-financial-officer-300097634.html
SOURCE Valeant Pharmaceuticals International, Inc.